Free Trial

Novo Nordisk A/S (NVO) Competitors

Novo Nordisk A/S logo
$54.41 -1.68 (-3.00%)
Closing price 10/17/2025 03:59 PM Eastern
Extended Trading
$54.66 +0.25 (+0.46%)
As of 10/17/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NVO vs. NVS, AZN, SNY, GSK, ARGX, TAK, ONC, INSM, BNTX, and TEVA

Should you be buying Novo Nordisk A/S stock or one of its competitors? The main competitors of Novo Nordisk A/S include Novartis (NVS), AstraZeneca (AZN), Sanofi (SNY), GSK (GSK), argenex (ARGX), Takeda Pharmaceutical (TAK), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

Novo Nordisk A/S vs. Its Competitors

Novartis (NYSE:NVS) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Novartis pays an annual dividend of $2.59 per share and has a dividend yield of 2.0%. Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 1.5%. Novartis pays out 37.7% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 22.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novo Nordisk A/S has lower revenue, but higher earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$55.19B5.03$11.94B$6.8719.13
Novo Nordisk A/S$42.12B5.77$14.64B$3.6414.95

Novartis presently has a consensus price target of $120.33, suggesting a potential downside of 8.46%. Novo Nordisk A/S has a consensus price target of $76.00, suggesting a potential upside of 39.69%. Given Novo Nordisk A/S's stronger consensus rating and higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novartis
3 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.10
Novo Nordisk A/S
1 Sell rating(s)
10 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
2.50

In the previous week, Novo Nordisk A/S had 33 more articles in the media than Novartis. MarketBeat recorded 58 mentions for Novo Nordisk A/S and 25 mentions for Novartis. Novartis' average media sentiment score of 1.38 beat Novo Nordisk A/S's score of 0.71 indicating that Novartis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novartis
20 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Novo Nordisk A/S
31 Very Positive mention(s)
7 Positive mention(s)
8 Neutral mention(s)
11 Negative mention(s)
0 Very Negative mention(s)
Positive

Novartis has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.

Novo Nordisk A/S has a net margin of 35.60% compared to Novartis' net margin of 25.64%. Novo Nordisk A/S's return on equity of 78.64% beat Novartis' return on equity.

Company Net Margins Return on Equity Return on Assets
Novartis25.64% 41.08% 16.83%
Novo Nordisk A/S 35.60%78.64%24.51%

13.1% of Novartis shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Novo Nordisk A/S beats Novartis on 13 of the 19 factors compared between the two stocks.

Get Novo Nordisk A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVO vs. The Competition

MetricNovo Nordisk A/SLarge Cap Pharma IndustryMedical SectorNYSE Exchange
Market Cap$242.76B$267.65B$6.19B$21.83B
Dividend Yield1.51%2.61%5.70%3.62%
P/E Ratio14.9530.8685.5432.43
Price / Sales5.775.11611.7860.31
Price / Cash13.9414.3237.1024.21
Price / Book11.6819.6112.234.59
Net Income$14.64B$8.49B$3.33B$1.02B
7 Day Performance-4.46%-0.77%1.17%1.31%
1 Month Performance-11.46%2.04%6.85%-0.93%
1 Year Performance-53.93%-4.82%58.93%9.51%

Novo Nordisk A/S Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVO
Novo Nordisk A/S
4.3779 of 5 stars
$54.41
-3.0%
$76.00
+39.7%
-53.9%$242.76B$42.12B14.9577,349Trending News
Analyst Forecast
Gap Down
NVS
Novartis
2.5323 of 5 stars
$129.52
-0.4%
$120.33
-7.1%
+12.2%$273.57B$55.19B18.8575,883News Coverage
Positive News
AZN
AstraZeneca
3.1428 of 5 stars
$84.47
-0.1%
$86.00
+1.8%
+8.2%$262.40B$56.50B31.8194,300Trending News
Analyst Downgrade
Short Interest ↓
Analyst Revision
SNY
Sanofi
4.2075 of 5 stars
$48.50
+0.9%
$62.67
+29.2%
-7.8%$119.23B$44.46B11.6782,878Upcoming Earnings
GSK
GSK
1.8515 of 5 stars
$43.51
-0.1%
$37.38
-14.1%
+14.0%$88.51B$31.63B20.1468,629Dividend Cut
ARGX
argenex
3.5861 of 5 stars
$801.69
+0.6%
$817.53
+2.0%
+49.3%$49.06B$3.05B41.111,599Analyst Revision
Gap Down
TAK
Takeda Pharmaceutical
3.3802 of 5 stars
$13.73
+0.1%
N/A-2.0%$43.67B$4.48T45.7547,455Analyst Forecast
ONC
BeOne Medicines
2.9541 of 5 stars
$331.12
+3.4%
$340.30
+2.8%
N/A$36.29B$3.81B-191.4011,000
INSM
Insmed
2.9311 of 5 stars
$164.69
+1.5%
$149.06
-9.5%
+122.4%$34.84B$363.71M-28.871,271News Coverage
Analyst Forecast
BNTX
BioNTech
2.6578 of 5 stars
$102.28
+0.2%
$134.32
+31.3%
-5.9%$24.61B$2.88B-63.976,772Analyst Forecast
TEVA
Teva Pharmaceutical Industries
3.5883 of 5 stars
$19.99
-0.2%
$25.57
+28.0%
+7.7%$23.01B$16.63B-125.4136,830

Related Companies and Tools


This page (NYSE:NVO) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners